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Abstract
Background: The occurrence of, and risk factors for, HHV-8 infection have yet to be definitively
determined, particularly among heterosexual individuals with at-risk behavior for sexually transmitted
infections (STI). The objective of this study was to estimate the incidence and determinants of HHV-8
infection among HIV-uninfected individuals repeatedly attending an urban STI clinic.
Methods: Sera from consecutive HIV-uninfected individuals repeatedly tested for HIV-1 antibodies were
additionally tested for HHV-8 antibodies using an immunofluorescence assay. To identify determinants of
HHV-8 infection, a nested case-control study and multivariate logistic regression analysis were performed.
Results: Sera from 456 HIV-uninfected individuals (224 multiple-partner heterosexuals and 232 men who
have sex with men (MSM]) were identified for inclusion in the study. The HHV-8 seroprevalence at
enrollment was 9.4% (21/224; 95% C.I.: 6.0–14.2%) among heterosexuals with multiple partners and 22.0%
(51/232; 95% C.I.: 16.9–28.0%) among MSM. Among the 203 multiple-partner heterosexuals and 181 MSM
who were initially HHV-8-negative, 17 (IR = 3.0/100 p-y, 95% C.I.: 1.9 – 4.8) and 21 (IR = 3.3/100 p-y, 95%
C.I:.2.1 – 5.1) seroconversions occurred, respectively. HHV-8 seroconversion tended to be associated
with a high number of sexual partners during the follow-up among MSM (> 10 partners: AOR = 3.32 95%
CI:0.89–12.46) and among the multiple-partner heterosexuals (> 10 partner; AOR = 3.46, 95%
CI:0.42–28.2). Moreover, among MSM, HHV-8 seroconversion tended to be associated with STI (AOR =
1.80 95%CI: 0.52–7.96).
During the study period the HIV-1 incidence was lower than that of HHV-8 among both groups (0.89/100
p-y among MSM and 0.95/100 p-y among multiple-partner heterosexuals).
Conclusion: The large difference between the incidence of HHV-8 and the incidence of HIV-1 and other
STIs may suggest that the circulation of HHV-8 is sustained by practices other than classical at-risk sexual
behavior.
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Background
The modes of transmission of human herpesvirus 8
(HHV-8), also known as "Kaposi's Sarcoma-associated
Herpesvirus" (KSHV), have yet to be clearly established.
Several studies have suggested that it may be transmitted
sexually, although the role of specific sexual practices have
yet to be conclusively defined. In areas of low endemicity,
such as North America and Northern Europe, HHV-8
infection appears to be concentrated among men who
have sex with men (MSM) at high risk of HIV-1 infection
and other sexually transmitted infections (STI), whereas it
is uncommon among persons who have not reached the
age of sexual activity [1,2]. Moreover, several prevalence
studies among MSM have reported an association
between HHV-8 infection and receptive anal sex, the
number of sexual partners, HSV-2 infection, hepatitis B
virus infection, a history of syphilis, and HIV-1 infection,
suggesting that the modes of transmission of HHV-8,
among MSM, are similar to those for common STIs [3-7].
However, the results of recent incidence studies among
MSM suggest that oro-genital sex, rather than receptive
anal sex, is an important mode of HHV-8 transmission [8-
10]. That the infection may be transmitted through saliva
or other types of casual contact has been suggested by
seroepidemiological studies which have reported a high
prevalence of HHV-8 infection among children in Sub-
Saharan Africa and, to some extent, in Mediterranean
countries [11,12]. The hypothesis of transmission
through saliva is also supported by the results of studies
showing that HHV-8 DNA sequences are more likely to be
detected in saliva or in mouth swabs than in semen or cer-
vical-vaginal swabs [13-16].
With regard to the potential for sexual transmission
among heterosexual individuals, little information is
available. Among heterosexual men living in areas where
the infection is endemic, a recent study has suggested that
sexual factors may play an important role [17]. Moreover,
cross-sectional studies of women with (or at risk of) HIV-
1 infection have identified a history of syphilis, HIV-1
infection, older age, black race, intravenous drug use, gon-
orrhea, and alcohol abuse as correlates of HHV-8 infec-
tion, whereas other studies have shown no evidence of
transmission through sexual contact [7,18-21].
Regarding the incidence of HHV-8 infection, two large
studies conducted among MSM, one in the U.S.A. and the
other in the Netherlands, have reported similar rates: 3.6
and 3.8/100 person-years, respectively, whereas there are
no published estimates of the incidence among non-intra-
venous-drug-using heterosexual men or women [5,22].
To estimate the prevalence and incidence of HHV-8 infec-
tion and to identify risk factors for seroconversion and
correlates of infection, we conducted a retrospective lon-
gitudinal study using frozen serum samples from non-
drug-using MSM and heterosexual men and women with
multiple partners who had repeatedly undergone HIV-1
testing at an important screening site in Rome, Italy.
Methods
Study population
The study participants were non-drug-using MSM and
multiple-partner heterosexuals who, between July 1, 1992
and June 30, 1999, had at least twice undergone voluntary
counseling & testing for antibodies against HIV-1 at an
inner-city STI Clinic. The study site is the largest STI clinic
in Rome, Italy, with a documented expertise in STI screen-
ing and control programs target to at-risk populations.
Multiple-partner heterosexuals were defined as individu-
als who reported that they had had at least 3 sexual part-
ners of the opposite sex in the 12 months prior to the first
test in the study period and that they had never injected
recreational drugs or engaged in homosexual intercourse
in their lifetime.
Information on behavioral risk factors for the transmis-
sion of HIV-1 was taken from the clinic's computerized
database. Data were collected by means of a standard
interview conducted during the pre-HIV-test counseling
session.
Given the evidence of a measurable risk of HHV-8 trans-
mission through blood or blood derivatives, we excluded
all individuals with a history of blood transfusion or the
use of blood-derivatives before the first HIV-test or during
the follow-up period [23-25].
Study design
A retrospective longitudinal study was conducted using
coded serum samples that had been collected from all eli-
gible individuals and stored at -80°C. The study consisted
of a cross-sectional phase for assessing the prevalence of
HHV-8 infection at enrollment and, among participants
who tested HHV-8-negative at enrollment, a longitudinal
phase for assessing the incidence of HHV-8 infection.
Laboratory procedures
Anti-HHV-8 immunofluorescence assay
Sera from all participants were tested for antibodies to
lytic antigens of HHV-8 using an immunofluorescence
assay (IFA) based on BCBL-1 cell line. In accordance with
Andreoni et al., sera reactive at a 1:20 dilution were con-
sidered as positive, so as to attain the optimal levels of
sensitivity and specificity of the test, as demonstrated in a
previous multicenter study [26,27].
For each antibody assay, aliquots of pooled negative
serum samples from 10 children (age 0–6 years) and ofBMC Infectious Diseases 2007, 7:143 http://www.biomedcentral.com/1471-2334/7/143
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positive serum samples from 5 HIV-negative KS patients
were included as additional controls.
HIV-1 antibody assay
Sera were tested for HIV-1 antibodies using an enzyme-
linked immunoabsorbent assay (ELISA Genelavia Mix,
Pasteur, France). Reactive sera were confirmed using a
Western blot test (Western Blot, NevLav Blot I, Sanofi-Pas-
teur, France).
Data analysis
The prevalence of HHV-8 infection was calculated based
on serostatus at enrollment, and the correlates of preva-
lent HHV-8 infection were assessed using 2 × 2 table anal-
ysis. The incidence rates were calculated using the person-
time method and were expressed in per 100/person year
(p-y) of follow-up. The follow-up period was considered
as the interval of time between the date of the first serum
sample and the date of the last sample. For HHV-8 sero-
converters, the follow-up period was defined as the time
elapsed from the first HHV-8-negative sample to the mid-
point in time between the last HHV-8-negative sample
and the first HHV-8 positive sample.
To identify risk factors for HHV-8 infection, seroconvert-
ers were compared with persistently HHV-8 negative indi-
viduals for selected clinical and behavioral characteristics,
using a nested case-control analysis. A multivariate logis-
tic regression analysis was applied to assess the independ-
ent role of the variables. All of the demographic,
behavioral and clinical data for the study participants
were extracted from the HIV-1 screening computerized
database.
The number of years of sexual activity was considered as a
dichotomous variable, determined using the median
value as the cut-off (less than the median value vs. greater
than or equal to this value).
Results
HHV-8 prevalence
During the study period, 456 HIV-uninfected Caucasian
individuals who consecutively visited the STI clinic were
eligible for enrollment in the study: 224 were multiple-
partner heterosexuals (185 males and 39 females) and
232 were MSM.
Overall, 72 of the 456 study participants (15.8%; 95% CI:
12.6%–19.5%) were HHV-8-seropositive upon enroll-
ment. The median age was 36 years (range: 20–70) for
prevalent HHV-8-infected individuals and 32 years
(range: 17–69) for HHV-8 uninfected individuals. The
seroprevalence of HHV-8 infection at enrollment was
9.4% (21/224; 95% CI: 6.0%–14.2%) among HIV-unin-
fected multiple-partner heterosexuals and 22.0% (51/
232; 95% CI: 16.9–28.0%) among HIV-uninfected MSM
(Table 1).
The persistence of positivity for HHV-8 antibodies over
time, was assessed among 53 out of the 72 individuals
who were HHV-8 positive at recruitment. Using serum
samples collected for sequential HIV-antibody test, HHV-
8 antibodies positivity was confirmed for 52 out of 53
HHV-8 positive individuals (98.1%).
Among the multiple-partner heterosexuals, the seropreva-
lence was higher among males (9.7%) than among
females (7.7%). No significant statistical associations
were found between HHV-8 seropositivity and the inves-
tigated behavioral variables. Nonetheless, higher HHV-8
rates were observed among younger multiple-partner het-
erosexuals (14.3% for age < 25 years) compared to those
who were older (Table 1). Moreover, HHV-8 seropreva-
lence tended to be higher for persons with: age at first sex-
ual intercourse of less than 17 years (OR = 1.57; 95% CI:
0.50–4.97); more than five sexual partners in the previous
year (OR = 1.90; 95% CI: 0.59–6.11); syphilis (OR = 2.98,
95% CI: 0.92–9.37; p < 0.05); and, among males, a his-
tory of urethral gonorrhea (OR = 2.29, 95% CI:
0.64–7.87) (Table 1).
Among MSM, HHV-8 seroprevalence tended to increase
with age (OR = 1.86, 95% CI: 0.48–10.60 for the 25–35-
year age group, and OR = 2.57, 95% CI: 0.69–14.32 for
the > 35-year age group); it also increased with the
number of years of sexual activity (OR = 1.54, 95% CI:
0.75–3.17 for more than 16 years) and with younger age
at first sexual contact (less than 17 years) (OR = 1.61,
95%CI:0.78–3.33); however, none of these associations
was statistically significant (Table 1). Moreover, among
MSM, HHV-8 infection also tended to be associated with
a higher number of sexual partners in the previous year
and with history of STIs, particularly gonorrhea (Table 1).
HHV-8 incidence
Overall, 384 of the study participants (203 multiple-part-
ner heterosexuals and 181 MSM) were initially negative
for HHV-8 antibodies and were thus included in the lon-
gitudinal seroincidence study. Of these participants, 348
(90.6%) were males. The median age at enrollment was
31 years (range: 17–69) for multiple-partner heterosexu-
als and 33.5 years (range: 19–61) for MSM. The median
duration of follow-up was 2.8 years overall (range:
0.4–7.0; it was 2.6 years (range: 0.4–7.0) for multiple-
partner heterosexuals and 3.2 years (range: 0.5–6.7) for
MSM.
Overall, 38 individuals seroconverted during the follow-
up period, of whom 36 (94.7%) were men. The HHV-8
incidence was 3.2/100 person-years (p-y) overall; it wasBMC Infectious Diseases 2007, 7:143 http://www.biomedcentral.com/1471-2334/7/143
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3.0/100 p-y (95% C.I.: 1.9–4.8) for multiple-partner het-
erosexuals and 3.3/100 p-y for MSM (95% C.I.:2.1–5.1).
(Table 2).
During the study period, 11 of the 384 individuals who
were negative for HIV-1 and HHV-8 and included in the
longitudinal study seroconverted for HIV-1, for an overall
seroincidence of 0.92/100 p-y. The incidence of HIV-1
was lower than that of HHV-8 among both multiple-part-
ner heterosexuals (0.89/100 p-y vs. 3.1/100 p-y, respec-
tively) and MSM (0.95/100 p-y vs. 3.2/100 p-y,
respectively). Moreover, for both groups, the incidence of
Table 1: Behavioral and virological characteristics of multiple-partner heterosexuals and of men who have sex with men (MSM) by 
HHV-8 antibody status at the enrollment.
MULTIPLE-PARTNER HETEROSEXUALS MSM
HHV-8+/T COR (95% C.I.) HHV-8+/T COR (95% C.I.)
All 21/224 (9.4%) (6.0%–14.2%) 51/232 (22.0%) (16.9%–28.0%)
Gender
Females 3/39 (7.7) 1.0 - -
Males 18/185 (9.7) 1.29 (0.35–7.21) 51/232 (22.0) -
Age group (years)
< 25 6/42 (14.3) 1.0 3/25 (12.0) 1
25–35 7/96 (7.3) 0.47 (0.13–1.84) 20/99 (20.2) 1.86 (0.48–10.60)
> 35 8/86 (9.3) 0.62 (0.17–2.33) 28/108 (25.9) 2.57 (0.69–14.32)
Age at sexual debut §
≥ 17 years 7/102 (6.9) 1.0 22/116 (19.0) 1
< 17 years 9/87 (10.3) 1.57 (0.50–4.97) 23/84 (27.4) 1.61 (0.78–3.33)
Yrs. of sexual activity§
Median (range) 14 (1–54) 16 (2–45)
< median value 10/99(10.1) 1.0 19/101 (18.8) 1
≥ median value 6/90(6.7) 0.64 (0.18–2.04) 26/99 (26.3) 1.54 (0.75–3.17)
No. of partners*
< 3 0/0 (-) - 7/41 (17.1) 1
3 8/62 (12.9) 1.0 6/30(20.0) 1.27 (0.31–4.72)
4–5 1/37 (2.7) 0.19 (0.00–1.52) 16/48 (33.3) 2.43 (0.80–7.57)
> 5 9/41 (21.9) 1.90 (0.59–6.11) 5/13 (38.5) 3.04(0.58–14.61)
History of STI**
Negative 12/143 (8.4) 1.0 22/109(20.2) 1
Positive 9/81 (11.1) 1.36 (0.50–3.68) 29/123(23.6) 1.22 (0.62–2.30)
History of cervical gonorrhea
Negative 3/38 (7.9) 1.0 - -
Positive 0/1 (0.0) N.A. - -
History of gonorrhea
Negative 13/156 (8.3) 1.0 37/184(20.1) 1
Positive 5/29 (17.2) 2.29 (0.64–7.87) 14/48 (29.2) 1.64 (0.74–3.57)
History of syphilis
Negative 15/194 (7.7) 1.0 37/156 (23.7) 1
Positive 6/30 (20.0) 2.98 (0.92–9.37)° 14/76 (18.4) 0.73 (0.34–1.53)
° p < 0.05.
COR: Crude Odds Ratio; N.A.: not applicable; *During the previous year; missing data for 84 Multiple partner heterosexual and 100 MSM; **The 
STIs investigated were: genital warts, unspecific urethral/vaginal infections, gonorrhea, syphilis and genital herpes. §Missing data for 32 MSM and 35 
Multiple-partner heterosexuals.
Table 2: Seroincidence of HHV-8 infection among 384 individuals repeatedly tested for HIV-1 by exposure group and gender.
Total cases Person-years (p-y) Number of seroconversions Incidence rate x100/p-y 95% C.I.*
ALL 384 1,193 38 3.2 2.3 – 4.4
M. P. H. 203 564 17 3.0 1.9 – 4.8
Males 167 476 15 3.1 1.9 – 5.1
Females 36 88 2 2.3 0.5 – 9.2
MSM 181 629 21 3.3 2.1 – 5.1
MSM: men who have sex with men; MPH: multiple-partner heterosexuals. * C.I.: confidence intervals.BMC Infectious Diseases 2007, 7:143 http://www.biomedcentral.com/1471-2334/7/143
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each of the STIs investigated during the follow-up period
(i.e., genital warts, unspecific urethritis, unspecific vaginal
infections, gonococcal infections, syphilis, and genital
herpes) was lower than the incidence of HHV-8 (data not
shown).
Among multiple-partner heterosexuals, when comparing
HHV-8 seroconverters to those who were persistently neg-
ative, no statistically significant differences were found in
terms of gender, age, HIV-1 seroconversion, or occurrence
of STIs (Table 3). Nonetheless, among multiple-partner
heterosexuals, HHV-8 seroconversion was linearly associ-
ated with the number of sexual partners during follow-up
(χ2 for trend = 3.37; p = 0.07). This association, though
not significant, was also shown in the logistic model
(AOR = 3.46; 95% CI: 0.42–28.2 partners > 10).
HHV-8 seroconversion was linearly associated with the
number of sexual partners during follow-up also among
MSM (χ2 for trend = 3.38; p = 0.066), and the association,
though not significant, was also shown in the logistic
model (AOR = 3.32 95% CI: 0.89–12.46). Among MSM
(Table 4), the risk of HHV-8 seroconversion also tended to
be independently associated with gonococcal infection
(AOR = 3.20 95% CI: 0.67–15.36).
Discussion
Our study provides information on the incidence and
prevalence of HHV-8 infection among HIV-uninfected
individuals at high-risk of acquiring STIs. To the best of
our knowledge, this is the first longitudinal study in an
economically developed country to provide estimates of
the incidence of HHV-8 infection among HIV-uninfected,
yet promiscuous, non-drug-using heterosexual individu-
als.
HHV-8 seroprevalence at enrollment was higher among
MSM, compared to multiple-partner heterosexuals, con-
firming the previously reported wider diffusion of the
infection among homosexual men. However, it remains
to be determined whether this difference was related to
differences in the level of promiscuity or in specific sexual
practices.
The HHV-8 seroprevalence among multiple-partner heter-
osexuals was lower than that reported in a study con-
ducted among HIV-negative heterosexuals attending an
STI clinic in another Mediterranean country (i.e., Spain),
yet it was twice as high as that reported among HIV-nega-
tive non-African heterosexuals (4.6%) attending an STI
clinic in London [28,7]. The seroprevalence among MSM
was higher than the rates reported in other industrialized
countries yet similar to those reported by other studies
conducted among MSM in Italy [4,8,9,29-31].
With regard to the incidence of HHV-8 infection, the rate
among MSM is consistent with the seroconversion rates
reported by other longitudinal studies conducted among
Table 3: HHV-8 attack rate and OR (crude and adjusted) of HHV-8 seroconversion by behavioral and virological characteristics of 203 
multiple-partner heterosexuals.
HHV-8 Serocon/T (%)N = 17/203 COR (95%C.I.) AOR (95%C.I.) P
Gender
Females 2/36 (5.5) 1.0 1.0
Males 15/167 (9.0) 1.68 (0.36–15.77) 1.46 (0.31–6.87) .630
Age **(years)
< 25 3/25 (12.0) 1.0 1.0
25–35 6/87 (6.9) 0.54 (0.13–2.35) 0.52 (0.11–2.37) .402
> 35 8/91 (8.8) 0.71 (0.17–2.90) 0.56 (0.13–2.50) .451
STI during follow-up
None 13/165 (7.9) 1.0 1.0
Any STI 4/38 (10.5) 1.38 (0.31–4.82) 1.56 (0.38–5.96) .586
Other STI ^ 3/31 (9.4) 1.25 (0.22–4.98) 1.36 (0.35–5.32) .657
Syphilis 0/6 (-) N.A.- -
Gonorrhea 1/1 (100.0) Undetermined - -
HIV-1 during follow-up
Non-seroconverted 17/198 (8.6) 1.0 - -
Seroconverted 0/5 (0.0) N.A. - -
No. sexual partners during follow-up
< 3 2/55 (3.6) 1.0 1.0
3–5 6/74 (8.1) 2.34 (0.45–12.05) 2.45 (0.47–12.7) .288
6–10 6/55 (10.9) 3.24 (0.62–16.84) 3.30 (0.62–17.4) .160
> 10 3/19 (15.8) 4.96 (0.76–32.35) 3.46 (0.42–28.2) .247
STI: Sexually Transmitted Infections; N.A.: not applicable;
** age at last test; ^ Other STI included: genital warts, unspecific urethral/vaginal infections, and genital herpes.BMC Infectious Diseases 2007, 7:143 http://www.biomedcentral.com/1471-2334/7/143
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the same group. The incidence rate found in our study was
similar to that among HIV-1-negative MSM in Seattle,
USA (3.8/100 p-y) and somewhat higher than that among
HIV-1-negative MSM in Amsterdam (2.6/100 p-y) [5,22].
As in other studies, none of the variables considered in
our study as proxies of at-risk sexual behavior were found
to have been associated with HHV-8 seroconversion
among MSM [7,8]. To this regard, it should be mentioned
that the study design was based on the investigation of a
cohort of individuals evaluated to identify risk factors for
HIV-1, and this may have limited the ability to detect
determinants for HHV-8 infection.
Surprisingly, the HHV-8 seroincidence among heterosex-
ual males was similar to that among MSM (3.1/100 vs.
3.3/100 p-y, respectively). Among heterosexuals, the
seroincidence rate was lower among females than males
(2.3/100 vs. 3.1/100 p-y), but the small number of events
among females does not permit any robust comparison
by gender.
There are no clear explanations for the inconsistency
between incidence and prevalence data. In fact, the preva-
lence data, which are the expression of cumulative infec-
tions, seem to suggest that sexual practices related to male-
to-male sex play an important role in the transmission of
HHV-8. However, our seroincidence data did not reveal
any excess risk related to male-to-male sex with respect to
male-to-female sex. This could be due to recent behavioral
changes or to a recent increase in the circulation of HHV-
8 among multiple-partner heterosexuals, as indicated by
the higher seroprevalence of HHV-8 among younger het-
erosexuals.
Furthermore, the higher risk of HHV-8 infection among
both MSM and multiple-partner heterosexual males, com-
pared with females, seem to suggests that insertive-penile
intercourse may play an important role in the acquisition
of the infection. This is somewhat consistent with studies
that have identified penile-oral sex, a common sexual
practice among both homosexual and heterosexual males,
as a risk factor for HHV-8 infection and have suggested
that the insertive partner is at greatest risk through contact
with saliva [19,20]. In fact, HHV-8-DNA has frequently
been detected in saliva, yet differently from HIV-1, it has
rarely been found in semen or vaginal fluids
[13,15,16,32].
Since it is well known that gonococcal uretrithis is effi-
ciently acquired through insertive oral sex among homo-
sexual and heterosexual males, the finding that prevalent
HHV-8 infection tended to be associated with gonorrhea
in both groups may indicate that this STI could be a bio-
logical marker of exposure to saliva during sex in both
groups. The lack of statistically significant results may
Table 4: HHV-8 attack rates and OR (crude and adjusted) of seroconversion by behavioral and virological characteristics of 181 men 
who have sex with men.
HHV-8 Serocon/T (%)N = 21/181 COR (95%C.I.) AOR (95% C.I.) P
Gender
Females -
Males 21/181 (11.2) N.A. N.A.
Age **(years)
< 25 1/7 (14.3) 1.0 1.0
25–35 9/71 (12.7) 0.87 (0.10–8.10) 0.69 (0.06–7.13) .758
> 35 11/103 (10.7) 0.72 (0.10–7.52) 0.53 (0.05–5.70) .599
STI during follow-up
None 16/154(10.4) 1.0 1.0
Any 5/27 (18.5) 1.96 (0.51–6.35) 1.80 (0.52–7.96) . 480
Other STI ^ 1/10 (10.0) 0.96 (0.02–7.76) 1.13 (0.13–9.96) .913
Syphilis 1/7 (14.3) 1.44 (0.03–13.05) 1.47 (0.15–14.13) .739
Gonorrhea 3/10 (30.0) 3.70 (0.56–18.11) 3.20 (0.67–15.36) .146
HIV-1 during follow-up
Non-seroconverters 20/175(11.4) 1.0 1.0
Seroconverters 1/6 (16.7) 1.55(0.03–14.87) 1.56 (0.16–15.69) .704
No. sexual partners during 
follow-up
< 3 4/55(7.3) 1.0 1.0
3–5 4/43(9.3) 1.30 (0.31–5.56) 1.41 (0.32–6.13) .647
6–10 4/36 (11.1) 1.59 (0.37–6.83) 1.50 (0.32–6.82) .601
> 10 9/47 (19.1) 3.02 (0.86–10.54) 3.32 (0.89–12.46) .075
STI: Sexually Transmitted Infections; N.A.: not applicable;
** age at the last test; ^ Other STI included: genital warts, unspecific urethral/vaginal infections and genital herpes.BMC Infectious Diseases 2007, 7:143 http://www.biomedcentral.com/1471-2334/7/143
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have been due to the limited power of the study resulting
from the relatively small numbers of events.
The finding that the overall HHV-8 seroincidence (3.2/
100 p-y) was more than three times higher than the over-
all HIV-1 seroincidence and that it was much higher than
the seroincidence of HIV-1 and other STIs among both
MSM and multiple-partner heterosexuals suggests that the
circulation of HHV-8 may be sustained by practices other
than those associated with the transmission of HIV-1 or
other STIs.
Before drawing conclusions, some limits and biases of the
study should be mentioned. First, not all the 72 individu-
als HHV-8 positive at enrollment were retested to confirm
antibodies persistence over time. Nevertheless, the high
proportion of confirmed positive results (98.1%) suggests
that incidence rates were not biased by eventual serorever-
sion. Second, information on certain sexual practices
involving contact with saliva, such as the frequency of
oral-penile contact or oral-anal contact was no collected
because not included in the individual behavioral data
form aimed to HIV risk assessment. Third, the seroconver-
sion rates may have been somewhat biased, given that
persons who undergo repeated HIV-1 testing represent a
self-selected population and to some extent may differ
from those who do not return after the first test. Reasona-
bly, we supposed that, in this study, the incidence rates of
HHV-8 infection represent an estimate of infection among
Mediterranean individuals who underwent repeated HIV-
1 testing because of their sexual risk behavior.
Lastly, the multiple partner heterosexuals in this cohort
may not have been representative of the general popula-
tion of sexually active heterosexuals; thus the HHV-8 sero-
conversion rates may have been overestimated and the
role of sexual transmission of infection inflated, especially
for those with more once partner.
In conclusion, in our study population, the seropreva-
lence of HHV-8 infection was lower among multiple-part-
ner heterosexuals than among MSM. The incidence of
HHV-8 infection did not differ between MSM and multi-
ple-partner heterosexual males, whereas a gender differ-
ence was found among heterosexuals. Among multiple-
partner heterosexuals, the findings that HHV-8 infection
tended to be associated with other STIs in the cross-sec-
tional study and with an increased number of partners in
the sero-incidence study seem to suggest that sexual
behavior plays a role in transmission. Nonetheless, addi-
tional longitudinal studies will need to be conducted to
better define the role of specific sexual practices in the
increase of risk of HHV-8 infection.
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